NORMAN J CLEMENT RPH., DDS, NORMAN L. CLEMENT PHARM-TECH, MALACHI F. MACKANDAL PHARMD, BELINDA BROWN-PARKER, IN THE SPIRIT OF JOSEPH SOLVO ESQ., INC.T. SPIRIT OF REV. IN THE SPIRIT OF WALTER R. CLEMENT BS., MS, MBA. HARVEY JENKINS MD, PH.D., IN THE SPIRIT OF C.T. VIVIAN, JELANI ZIMBABWE CLEMENT, BS., MBA., IN THE SPIRIT OF THE HON. PATRICE LUMUMBA, IN THE SPIRIT OF ERLIN CLEMENT SR., EVELYN J. CLEMENT, WALTER F. WRENN III., MD., JULIE KILLINGSWORTH, RENEE BLARE, RPH, DR. TERENCE SASAKI, MD LESLY POMPY MD., CHRISTOPHER RUSSO, MD., NANCY SEEFELDT, WILLIE GUINYARD BS., JOSEPH WEBSTER MD., MBA, BEVERLY C. PRINCE MD., FACS., NEIL ARNAND, MD., RICHARD KAUL, MD., IN THE SPIRIT OF LEROY BAYLOR, JAY K. JOSHI MD., MBA, AISHA GARDNER, ADRIENNE EDMUNDSON, ESTER HYATT PH.D., WALTER L. SMITH BS., IN THE SPIRIT OF BRAHM FISHER ESQ., MICHELE ALEXANDER MD., CUDJOE WILDING BS, MARTIN NJOKU, BS., RPH., IN THE SPIRIT OF DEBRA LYNN SHEPHERD, BERES E. MUSCHETT, STRATEGIC ADVISORS

SUMMARY

The limited research on diamorphine’s efficacy and the pervasive stigma surrounding sickle cell pain medication highlight significant healthcare gaps. This underscores the urgent need for improved healthcare systems and policies to address health disparities.

This research report further investigates the unique use of diamorphine (heroin) in British medical practice, focusing on its application beyond opioid addiction treatment.

One source examines the under-researched use of diamorphine (heroin) in British medical practice, focusing on its application beyond addiction treatment and highlighting concerns about respiratory depression. 

 A Second source Embraces the Complexity of Medicine’s significant health disparities faced by sickle cell disease patients, particularly within the Black community, focusing on inadequate pain management due to systemic racism and resulting in high hospitalization rates and costs. 

The study surveyed 141 medical practitioners to gather data on diamorphine’s use for various medical conditions, including the frequency, dosage, administration routes, and reported side effects. Results indicated widespread use, primarily for pain relief in conditions like myocardial infarction and palliative care.

While most doctors found diamorphine useful, concerns centered on respiratory depression. This highlights the need for further research to understand its clinical applications better and inform future regulatory decisions. The study acknowledges limitations in its sampling methodology.

Both sources emphasize the need for further research and address the critical lack of equitable access to appropriate healthcare and pain management. 

TREATMENT AND CARE GUIDED BY MIS-INFORMATION AND DYSTOPIAN FICTION COSTING THE LIFE OF MANY

Sickle cell disease (SCD) remains one of the most prevalent genetic health issues affecting people in the United States, with an estimated 100,000 individuals diagnosed, primarily within the Black community.

Recently, on “The WAOK Morning Show,” guest host Angela Greene spoke with Board Member and Sickle Cell Subcommittee Member Glinda Dames-Fincher about the critical health disparities associated with this disease, particularly how socioeconomic and racial factors influence treatment accessibility and quality of care.

TO LISTEN TO THE FULL INTERVIEW, CLICK HERE.

SICKLE CELL DISEASE’S DISPROPORTIONATE IMPACT RAISES ALARMS AND DISCUSSIONS

The Centers for Disease Control and Prevention (CDC) reports that SCD disproportionately impacts non-Hispanic Black or African American populations, with the condition seen in 90% of diagnosed individuals.

This leads to alarming statistics: those living with SCD typically face life expectancies that are over 20 years shorter than the national average.

This gap underscores the urgent need for enhanced healthcare screenings and interventions tailored to this demographic, which frequently experiences inadequate access to appropriate medical care.

Outline and Understanding the Diseases of Sickle Cell and Variations

TYPES OF ANEMIA’S

Essential Understanding: Definition, Pathophysiology, Clinical & Lab Findings, Treatment

A. Sickle Cell Disease Lecture

B. Sickel Cell Thalassemia

One point of concern raised in the discussion was the acute pain crisis that patients with sickle cell disease endure. These unpredictable episodes can arise suddenly and lead to excruciating pain due to the sickling of red blood cells, which obstructs blood flow and starves tissues of oxygen.

Yet, many patients face challenges when seeking pain management. A significant aspect of the interview focused on the stigma surrounding the disease, especially when patients seek relief through emergency medical services.

There persists a troubling perception problem; patients frequently face skepticism regarding their need for pain medications like opioids.

SICKLE CELL DISEASE, WHERE THE GENERATED PAIN LAUGHS AT MORPHINE

Such discrimination can lead to delays in urgent care, exacerbating the pain and suffering of patients.

Fincher’s conversation shed light on a concerning statistic: the treatment and management of SCD result in approximately 75,000 hospitalizations annually, costing the healthcare system an estimated $1.6 billion.

Such financial implications raise questions about how resources are being utilized to address not just SCD but the systemic inequities that plague health outcomes for African American patients.

Moreover, the discussion emphasized the complications arising from sickle cell disease, including stroke, kidney and liver damage, as well as lung and heart complications.

DIAMORPHINE BACKGROUND USE IN BRITAIN

Diamorphine (heroin) is unique to the UK because it is routinely used in clinical practice to treat medical conditions. This practice is not well-known outside of the UK.

Diamorphine is used to treat opiate addiction and is used in general medicine, but these two uses are distinct. For example, one overview of opiate substitution treatment in Europe claimed that 500 individuals were being treated with heroin prescribed by general practitioners in the UK. This is misleading because it confuses treatment for addiction with the treatment of medical conditions.

Diamorphine is unavailable for medical use in most countries and is prohibited in many countries. For example, it was banned in the US via the Narcotic Control Act of 1956.

The Compassionate Pain Relief Act of 1985 attempted to reintroduce it into US medicine but failed. Attempts were also made to prohibit the medical use of diamorphine in the UK during the 1950s.

AN UNDERSTANDING THE ROLE OF PRESCRIPTION DIAMOPHINE THROUGH DISCUSSION IN THE COMPLEXITIES OF MEDICINE

and

One major ethical implication is the potential for unequal access to effective pain relief. While diamorphine is recognized for its potent analgesic properties, particularly in managing acute pain conditions like myocardial infarction, its unavailability in most countries may limit treatment options for patients experiencing severe pain.

This disparity raises concerns about equitable access to appropriate medical care, potentially leaving patients in certain regions without access to a potentially beneficial medication due to legal restrictions rather than medical considerations.

Furthermore, the sources highlight a stigma surrounding opioid medications, particularly for patients with conditions like sickle cell disease, who often face skepticism and discrimination when seeking pain relief. This stigma, coupled with diamorphine’s prohibited status in many countries, could exacerbate challenges for patients needing effective pain management. (1) (2)

_______________________________/

1. Psychedelic rituals practices/ the god within: https://x.com/i/spaces/1vOxwrvdodRJB
2. Trust in Science / DISINFORMATION ON OPIOD October 3, 2024, Twitter Webinar, Dr Liza Dunn #PainCareCrisis https://x.com/drlizamd/status/1829964975097725045?s=46

It underscores the need for culturally sensitive approaches to pain management and education to address biases and ensure patients receive adequate care regardless of their condition or geographical location.

A PAIN THAT LAUGHS AT MORPHINE

These serious health issues underline the imperative for comprehensive management plans, including access to regular screenings and personalized treatment options.

The healthcare system’s response has often been littered with gaps, as many diseases, including sickle cell, do not receive the same funding or research support as other comparable conditions.

PHARMACISTS, PAIN CARE PROFILING, AND DISCRIMINATION THE RESULT OF REGULATORY RACISM

Dr. Wayne A. I. Frederick, M.D., MBA,  Charles R. Drew, professor of surgery and Howard University president, was elected to the National Academy of Medicine (NAM).  

According to NAM, Dr. Frederick was chosen “for being a tireless and gifted higher education leader, health care administrator, and world-renowned surgeon. As president of Howard University, he has worked to develop a diverse healthcare workforce while advising U.S. and international officials in navigating the COVID-19 pandemic.” 

However, Dr. Wayne A. I. Frederick, MD, President of Howard University, revealed that he has Sickle Cell Anemia. Dr. Frederick has said that he takes precautions to ensure he is adequately hydrated and has Motrin in case of a crisis. He also stated that he feared having a crisis outside of Washington DC and presenting to an Emergency Room where he could be accused of “drug seeking” and not be given opiate pain medication to treat his pain. 

His story is real and illustrates the anxiety patients with a history of chronic pain face every day and the threat to their very lives that DOJ-DEA aberrant policies pose. The DEA is not a medical entity and has no authority to limit treatment and treatment options within the medical community.

MUZIC & MEDICINE

SICKLE CELL ANEMIA GLENDA DAMES FINCHER

DONATE LEGAL DEFENSE

OR SEND

TO CASH APP:$docnorm

ZELLE 3135103378

ALL WATCHED OVER BY MACHINES OF LOVING GRACE

BE SURE TO DONATE TO THE MARK IBSEN GOFUNDME DEFENSE FUND, WHERE THE SON ALWAYS RISES!!!

FOR NOW, YOU ARE WITHIN

THE NORMS

REFERENCES:

• Seale, B. (1991, reprint of Random House 1970 edition). Seize the time: the story of the Black Panther Party and Huey P. Newton. Baltimore: Black Classic Press.
• Serjeant, G. R. (2010). One hundred years of sickle cell disease. British Journal of Haematology, 151(5), 425–429.Article Google Scholar 
• Tikkanen, R. S., Woolhandler, S., Himmelstein, D. U., Kressin, N. R., Hanchate, A., Lin, M., McCormick, D., & Lasser, K. E. (2017). Hospital payer and racial/ethnic mix at private academic medical centers in Boston and New York City. International Journal of Health Services, 47(3), 460–476. https://doi.org/10.1177/0020731416689549.Article Google Scholar 
• Ward Jr., T. (2017). Out in the rural: a Mississippi Health Center and its war on poverty. New York: Oxford University Press.Book Google Scholar 
• Williams, J. (2013). From the bullet to the ballot: the Illinois Chapter of the Black Panther Party and Racial Coalition Politics in Chicago. Chapel Hill, NC: University of North Carolina Press.Google Scholar 
• Williams, D. R., & Jackson, P. B. (2005). Social sources of racial health disparities. Health Affairs, 24(2), 325–334. https://doi.org/10.1377/hlthaff.24.2.325.Article Google Scholar 
• Williams, Y., & Lazerow, J. (2008). Liberated territory: untold local perspectives on the Black Panther Party. Chapel Hill, NC: Duke University Press.Book Google Scholar 
• Williams, D. R., Lawrence, J. A., & Davis, B. A. (2019). Racism and health: evidence and needed research. Annual Review of Public Health, 40, 105–125.Article Google Scholar 
• World Health Organization (1946). Constitution. Adopted in New York City, July 24, 1946. Text from WHO website. Retrieved August 25, 2019 (https://www.who.int/about/who-we-are/constitution).
• Young, Q., with S. Fiffer (2016). Quentin Young on the Black Panther Party Free Clinic in Chicago. American Journal of Public Health 106(10), 1754-1755. [Excerpted from Young, Q. (with S. Fiffer). Everybody In, Nobody Out: Memoirs of a Rebel Without a Pause. Friday Harbor, WA: Copernicus Healthcare, pp. 114–118, 2013.]

Briefing Notes and Document: The Unique Role of Diamorphine in British Medical Practice

Source: Gossop, M., Keaney, F., Sharma, P., & Jackson, M. (2005). The Unique Role of Diamorphine in British Medical Practice: A Survey of General Practitioners and Hospital Doctors. Eur Addict Res, 11(2), 76–82.

Main Themes:

• Unique Practice: The United Kingdom stands out globally for its routine use of diamorphine (heroin) in general medical practice. This practice, while commonplace in the UK, is often misunderstood or unknown in other countries where diamorphine is strictly prohibited for medical use.
• Distinct Applications: This study clarifies the distinction between diamorphine use for treating opioid addiction (infrequent and specialized) and its use for treating various medical conditions (routine).
• Common Applications: The survey highlights diamorphine’s frequent use for conditions like myocardial infarction, palliative care, pulmonary edema, and postoperative pain. Dosages, administration routes, and treatment durations vary depending on the condition.
• Perceptions and Concerns: While most surveyed doctors express no significant concerns regarding diamorphine prescription, worries about respiratory depression and addiction are present, especially among hospital doctors. Notably, GPs exhibit greater comfort with higher dosages and palliative care applications.
• Adverse Effects: Respiratory depression is the most frequently observed adverse effect, more commonly reported by hospital doctors than GPs.
• Need for Research: Despite widespread use, evidence-based research on diamorphine’s effectiveness for various medical conditions is scarce. This lack of robust data may impact future regulations and prescribing practices.

Key Ideas/Facts:

• Diamorphine has a long history in British medicine, dating back over a century.
• The drug is readily available and considered a standard medication in the UK.
• “Diamorphine is unavailable for medical use in most other countries. In many countries, it is specifically prohibited.”
• “Within the UK, the medical uses of diamorphine are so completely taken for granted that the practice has been the subject of very little research attention and has tended to remain ‘invisible’.”
• Myocardial infarction was the most frequent condition diamorphine was prescribed for.
• “Diamorphine was used to treat other conditions by 19% of the doctors. Other conditions for which diamorphine was used in more than a single case included painful sickle cell crisis (9 cases), sedation in intensive care (2 cases), and treatment of acute pain (2 cases).”
• Typical diamorphine doses ranged between 2 and 5 mg.
• “Diamorphine has been described as having important advantages over morphine when injections are required and especially when high doses are required.”
• “Diamorphine is also used by physicians in primary care…GPs were more likely to have prescribed higher doses of the drug and they were also more likely than the hospital doctors to have prescribed diamorphine for palliative care.”
• 51% of surveyed doctors reported observing at least one adverse effect.
• Respiratory depression was the most common adverse effect, particularly noted by hospital doctors and anaesthetists.
• “GPs were less likely than other doctors to report having observed respiratory depression after prescribing diamorphine…This is important since having observed respiratory depression was the single factor which was most strongly related to worries about the use of diamorphine.”

Implications:

• The unique British practice of routinely using diamorphine in medicine necessitates clear communication and understanding, especially in international contexts, to avoid misconceptions.
• With potential regulatory changes on the horizon, robust research is crucial to inform evidence-based decisions about diamorphine use and ensure optimal patient care. This includes addressing knowledge gaps about its effectiveness, long-term impacts, and potential for addiction in various medical applications.

Further Research:

• Comparative studies evaluating diamorphine’s efficacy against alternative medications for specific medical conditions.
• Long-term follow-up studies assessing the potential for addiction and dependence in patients receiving diamorphine for various medical reasons.
• Qualitative research exploring patients’ experiences and perceptions of diamorphine use in medical settings.

Conclusion:

This study illuminates the unique and largely unexamined practice of diamorphine use in British medicine. While the drug is established in clinical practice, more research is needed to solidify its evidence base and inform future policy decisions.

Briefing Document: Sickle Cell Disease Pain Management and the Diamorphine Question

Source 1: Excerpts from “Pasted Text” (author and publication details missing)

Source 2: Gossop, M., Keaney, F., Sharma, P., & Jackson, M. (2005). The Unique Role of Diamorphine in British Medical Practice: A Survey of General Practitioners and Hospital Doctors. Eur Addict Res, 11(2), 76–82.

Main Themes:

• Sickle Cell Disease Disparities: Source 1 highlights the significant healthcare disparities experienced by individuals with Sickle Cell Disease (SCD), particularly within the Black community in the United States.
• Pain Crisis Stigma: A major theme is the stigmatization surrounding SCD pain management, leading to distrust and inadequate treatment, particularly in emergency settings. Patients often face skepticism about their pain levels and are labeled as “drug-seekers,” resulting in delayed or denied pain relief.
• Socioeconomic and Racial Barriers: The source emphasizes the socioeconomic and racial factors contributing to unequal access to quality care and appropriate pain management for SCD.
• Cost Burden: The financial strain of SCD on the healthcare system is highlighted, raising questions about resource allocation and the need for more effective management strategies.
• Diamorphine in British Medical Practice: Source 2 explores the unique use of diamorphine (heroin) in routine UK medical practice.
• Wide Usage: Diamorphine is widely prescribed for various conditions, including myocardial infarction, palliative care, and even acute pain management.
• Dosage and Administration: The research details typical dosages and administration methods, noting variations based on the specific medical condition.
• Perceptions and Concerns: While generally accepted, concerns exist regarding respiratory depression and addiction potential. Interestingly, General Practitioners (GPs) appear more comfortable with diamorphine compared to hospital doctors.

Connecting The Themes By Shedding The Light Through Discussions and Embracing The Complexities of Medicine:

While seemingly disparate, these sources converge on a critical issue: the need for adequate pain management for serious medical conditions. Source 1 highlights the systemic failures in addressing the excruciating pain experienced by SCD patients. At the same time, Source 2 provides a potential solution—diamorphine—which is readily used in the UK but remains controversial elsewhere.

Key Facts and Quotes:

• Source 1:“The treatment and management of SCD result in approximately 75,000 hospitalizations annually, costing the healthcare system an estimated $1.6 billion.”
• “A PAIN THAT LAUGHS AT MORPHINE” – Emphasizing the severity of SCD pain.
• “People are dying needlessly from being profiled as drug addicts because of DEA Criminalization of our medications.” – Highlighting the tragic consequences of pain management stigma.
• Source 2:“Diamorphine is unavailable for medical use in most other countries. In many countries, it is specifically prohibited.”
• “Diamorphine has been described as having important advantages over morphine when injections are required and especially when high doses are required.”
• “GPs were less likely than other doctors to report having observed respiratory depression after prescribing diamorphine.” – Suggesting a nuanced understanding of the drug’s effects.

Implications and Future Directions:

• Addressing Pain Management Stigma: Urgent action is needed to dismantle the stigma surrounding pain management for SCD patients. Education, cultural sensitivity training, and evidence-based protocols are crucial for healthcare providers.
• Investigating Diamorphine for SCD Pain: Research exploring the potential benefits and risks of diamorphine for SCD pain management is warranted. Controlled trials comparing its efficacy and safety profile against existing treatments are needed.
• Policy Reform and Advocacy: Advocating for policy changes that prioritize patient well-being over unfounded fears of addiction is essential. The UK’s experience with diamorphine offers valuable insights for informing policy discussions globally.
• https://x.com/drlizamd/status/1829964975097725045?s=46

Conclusion:

These sources illuminate the critical need for equitable and effective pain management solutions, particularly for marginalized communities suffering from debilitating conditions like SCD. The potential of diamorphine in this context deserves further investigation and open discussion, challenging existing prejudices and prioritizing patient needs above all else.

The Unique Role of Diamorphine in British Medical Practice: A Content Summary

Source: Gossop, M., Keaney, F., Sharma, P., & Jackson, M. (2005). The unique role of diamorphine in British medical practice: A survey of general practitioners and hospital doctors. European Addiction Research, 11(2), 76–82.

I. Introduction: This section establishes the historical context of diamorphine (heroin) use in British medicine, highlighting its long-standing acceptance for general medical conditions in contrast to its controversial status in other countries. It differentiates between the use of diamorphine for opioid addiction treatment and its use for managing medical conditions, noting frequent misunderstandings surrounding these distinct practices.

II. Historical Background: This part delves into the history of diamorphine, from its synthesis in 1874 to its initial marketing and the diverse range of medical conditions it was used to treat in the early 20th century. It also touches upon the historical and current regulations surrounding diamorphine prescription in the UK, particularly for opioid addiction, referencing relevant committees and guidelines.

III. Contemporary European Context: This section briefly examines the renewed interest in prescribing diamorphine as a treatment for opioid addiction in countries like Switzerland and the Netherlands, citing results from large-scale clinical trials. It observes the relatively lower demand for diamorphine treatment in these trials, possibly due to the requirement for supervised administration.

IV. Study Purpose and Methods: This part outlines the aims of the present study, focusing on understanding how diamorphine is used in general medicine in the UK. It describes the study design, including the sample population (general practitioners and hospital doctors), data collection methods (self-completion questionnaire), and the specific data points collected (conditions treated, dosage, administration routes, duration of treatment, concerns, and adverse effects).

V. Results: This section presents the findings of the study, organized around key themes:

• Prescribing Practices: Details are provided on the number of patients prescribed diamorphine by the participating doctors, the most common medical conditions diamorphine was prescribed for (myocardial infarction, palliative care, pulmonary oedema, post-operative pain), typical dosages, routes of administration (intravenous, intramuscular, subcutaneous infusion), and the duration of treatment for each condition.
• Dosage Variations: This subsection highlights variations in diamorphine dosage based on medical specialty, noting that GPs tended to prescribe higher doses, especially for palliative care, compared to hospital doctors.
• Concerns and Reservations: This section explores the concerns reported by doctors regarding diamorphine prescription. It reveals that a majority expressed no reservations, while those who did primarily worried about respiratory depression or respiratory arrest. Concerns about addiction were relatively infrequent, particularly among GPs.
• Adverse Effects: This subsection details the observed adverse effects associated with diamorphine administration, with respiratory depression being the most commonly reported. It points out that hospital doctors, particularly anesthetists, were likelier to observe adverse effects than GPs. A statistical analysis links the observation of respiratory depression with increased concerns about prescribing diamorphine.

VI. Discussion: This section discusses the implications of the findings, contextualizing them within existing literature on diamorphine use in medicine.

• Common Uses and Dosage Patterns: It reiterates the common medical conditions diamorphine is used for and emphasizes the typical dosage patterns associated with each condition, drawing support from medical texts and guidelines.
• Palliative Care and Pain Management: This subsection discusses the wide acceptance of diamorphine in palliative care, particularly its advantages over morphine for pain relief in terminal patients.
• GPs vs. Hospital Doctors: It revisits the differences observed between GPs and hospital doctors in their diamorphine prescribing practices and concerns, suggesting possible reasons for these discrepancies.
• Adverse Effects and Concerns: This part acknowledges adverse effects, highlighting respiratory depression as the most significant concern. It speculates on the reasons for the differences in the reporting of adverse effects between GPs and hospital doctors.
• Addiction Concerns: This subsection addresses the relatively low levels of concern regarding addiction reported by doctors, attributing it to the typically short-term nature of diamorphine prescription for most conditions.

VII. Study Limitations: This section acknowledges the study’s limitations, such as the non-random sample selection and the lack of data on doctors who do not prescribe diamorphine. It cautions against overgeneralizing the findings due to these limitations.

VIII. Conclusion: The conclusion summarizes the study’s key findings, emphasizing the long-standing acceptance and routine use of diamorphine in British medical practice. It highlights the need for more evidence-based research to inform future decisions regarding diamorphine regulation and use, especially given the potential for increased scrutiny and tighter control measures.

https://www.jstor.org/stable/26790305

FAQ: Diamorphine in British Medical Practice

1. What is unique about the use of diamorphine (heroin) in British medical practice?

Unlike most other countries, the UK routinely uses diamorphine for general medical conditions. This practice is separate from its use in opioid addiction treatment, which is infrequent and strictly regulated.

2. For what medical conditions is diamorphine typically prescribed in the UK?

The four main conditions for which diamorphine is prescribed are:

• Myocardial Infarction: To relieve pain.
• Palliative Care: For pain management, often via subcutaneous infusion.
• Pulmonary Oedema: As a single intravenous dose.
• Post-Operative Pain: Administered intramuscularly.

3. How common is the prescription of diamorphine for these conditions?

Diamorphine is widely prescribed in the UK. Many doctors report having prescribed it to over 50 patients in their careers, with some exceeding 100 patients. The frequency of prescription varies based on the condition and setting (hospital vs. primary care).

4. Are there concerns regarding the potential for addiction with diamorphine prescription?

While diamorphine is associated with addiction, the majority of doctors surveyed expressed no significant concerns regarding addiction in medical use. This is likely because it is often prescribed in single doses or for palliative care, where the benefits of pain relief outweigh the addiction risk.

5. What are the main concerns doctors have about prescribing diamorphine?

The most common worry associated with diamorphine prescription is respiratory depression or failure. This concern is more prevalent among hospital doctors, who have more opportunities to observe such adverse effects than GPs.

6. Are there differences in diamorphine prescription patterns between General Practitioners (GPs) and hospital doctors?

Yes, GPs tend to prescribe higher doses of diamorphine, particularly for palliative care. They also express fewer concerns about its use compared to hospital doctors.

7. Are there any notable differences in observing adverse effects between medical specialties?

Hospital doctors, particularly those working in general medicine, surgery, and anesthesiology, are significantly more likely to observe adverse effects of diamorphine compared to GPs. This may be due to the different clinical settings and opportunities for observation.

8. What is the future for using diamorphine in British medical practice?

While diamorphine is currently widely used in the UK, ongoing reviews of controlled drug regulations and a push towards evidence-based medicine might influence its future use. More research on its effectiveness for various medical conditions is needed to solidify its place in British medical practice.

The Use of Diamorphine in British Medical Practice: A Study Guide

Quiz

Instructions: Please answer the following questions in 2-3 sentences each.

1. How does the article distinguish between the two primary uses of diamorphine in British medical practice?
2. Why is the routine clinical use of diamorphine considered unique to the UK?
3. What are the four main medical conditions for which diamorphine is prescribed, as identified in the study?
4. Describe the typical dosage and administration routes for diamorphine in treating myocardial infarction.
5. How does the duration of diamorphine prescribing differ between treatments for myocardial infarction and palliative care?
6. What was the most common worry reported by doctors regarding diamorphine prescription?
7. Which group of doctors, GPs or hospital doctors, reported higher levels of worry about diamorphine prescribing? Explain a possible reason for this difference.
8. What is the most frequently observed adverse effect associated with diamorphine administration?
9. Why might GPs be less likely to report observing respiratory depression as a side effect compared to hospital doctors?
10. What does the article suggest as the most crucial factor in determining the future of diamorphine use in medicine?

Quiz Answer Key

1. The article distinguishes between using diamorphine for treating opiate addiction and its use within general medicine for various medical conditions. These uses are distinct but often confused.
2. Diamorphine is unique to the UK because its medical use is prohibited or unavailable in most other countries, including the USA, where it was banned in 1956.
3. The four main conditions are myocardial infarction, palliative care, pulmonary edema, and post-operative pain.
4. For myocardial infarction, diamorphine is typically administered in a single intravenous dose of 2-5 mg.
5. For myocardial infarction, diamorphine is typically a single dose, while in palliative care, it is often prescribed for extended periods, potentially exceeding a month, via subcutaneous infusion.
6. The most common worry reported by doctors was the potential for respiratory depression or respiratory failure.
7. Hospital doctors reported higher levels of worry than GPs. This could be attributed to hospital doctors having more opportunities to observe adverse effects in a controlled environment.
8. The most frequently observed adverse effect is respiratory depression.
9. GPs might be less likely to report observing respiratory depression because they have fewer opportunities for extended patient observation in their typical practice setting than hospital doctors.
10. The article emphasizes the need for more well-controlled trials to establish diamorphine’s effectiveness in treating specific medical conditions. This evidence-based approach is crucial for determining its future in medicine.

Essay Questions

1. Discuss the historical context of diamorphine use in medicine, including its initial applications and the subsequent shifts in perception and regulation.
2. Analyze the reasons for the unique position of diamorphine in British medical practice compared to other countries. Consider the social, political, and cultural factors that might contribute to these differences.
3. Critically evaluate the ethical considerations surrounding the use of diamorphine in palliative care. Discuss the balance between pain relief, potential side effects, and quality of life for terminally ill patients.
4. Compare and contrast the advantages and disadvantages of using diamorphine versus morphine for pain management in different medical contexts. Refer to specific conditions and treatment goals in your analysis.
5. Explore the potential for bias in the study’s findings, considering the sampling methodology and the reliance on self-reported data from doctors. Suggest ways to address these limitations in future research on diamorphine use.

Glossary of Key Terms

• Diamorphine: The chemical name for heroin, a potent opioid analgesic derived from morphine.
• Myocardial Infarction: A heart attack occurs when blood flow to a part of the heart is blocked, causing damage to the heart muscle.
• Palliative Care: A specialized medical approach focused on improving the quality of life for patients with serious and life-limiting illnesses through pain and symptom management.
• Pulmonary Edema is characterized by fluid build-up in the lungs, making breathing difficult.
• Post-operative Pain: Pain experienced after a surgical procedure.
• Intravenous Injection (i.v.): Medication administration directly into a vein.
• Intramuscular Injection (i.m.): Administration of medication into a muscle.
• Subcutaneous Infusion: Slow, continuous delivery of medication under the skin, often using a pump.
• Respiratory Depression: A potentially serious side effect of opioids, marked by slowed breathing and decreased oxygen levels in the blood.
• Addiction/Dependence: A chronic, relapsing disease characterized by compulsive drug seeking and use despite harmful consequences.

Diamorphine (heroin) is unique in British medical practice because it is routinely used to treat several general medical conditions. This practice is not well-known outside the UK. While diamorphine is also sometimes used as a maintenance treatment for opiate addiction, this use is infrequent and distinct from its use for treating general medical conditions.

The routine clinical use of diamorphine for medical conditions is unique to the UK. In many countries, including the USA, the medical use of diamorphine is specifically prohibited. Diamorphine was first synthesized in the UK in 1874 and marketed as a medicine in 1898. Early reports recommended its use for a wide range of systemic and local conditions, including:

●

bronchitis

●

pneumonia

●

whooping cough

●

laryngitis

●

hay fever

●

angina pectoris

●

heart failure

●

aortic aneurysm

●

dysphagia

●

cancerous stomach

●

influenza

●

multiple sclerosis

●

gynecological diseases

●

inducing labor

●

narcosis

●

fever

●

high blood pressure

●

diabetes

●

dementia

●

depression

●

psychosis.

Although attempts have been made to prohibit the use of diamorphine in the UK, no prohibition has been introduced.

The British medical use of diamorphine for opiate addiction is quite different from its use for other medical conditions. The practice of prescribing diamorphine to opiate addicts has not been widely used in the UK, except for a short period after the establishment of the clinic system (1968–1974). In 1999, UK Department of Health guidelines stated that there was very little clinical indication for prescribed heroin as a treatment for opiate addiction. The drug may only be prescribed for this purpose in the UK by physicians with special Government licenses.

In contrast, diamorphine is widely used in general medicine in routine clinical practice in Britain to treat conditions such as:

●

myocardial infarction

●

palliative care

●

pulmonary edema

●

Post-operative pain.

The most frequent conditions for which doctors prescribe diamorphine are those that require pain relief. The specific conditions for which diamorphine is most often prescribed include those requiring palliative care, myocardial infarction, and postoperative pain.

The nature of prescribing diamorphine varies depending on the circumstances and conditions being treated. When used to relieve pain associated with myocardial infarction or for the treatment of pulmonary edema, diamorphine is typically given as a single intravenous dose of 2-5 mg. When used for palliative care, diamorphine is typically administered by subcutaneous infusion, in repeated doses, and over varying periods. Most doctors report that they are willing to prescribe diamorphine for periods of more than a month for palliative care.

Diamorphine is preferred over morphine in palliative care when injections are required, especially when high doses are required because it is more soluble and can be given in a smaller volume. It also causes less nausea and hypotension than morphine.

British physicians have a relaxed attitude towards diamorphine, and they use it with newborn infants, children, and adults. Diamorphine has been used intravenously and subcutaneously as an analgesic with children in accident and emergency units and to treat acute post-operative pain after abdominal surgery.

Doctors in the UK do not generally express unusual levels of concern about the adverse effects or side effects of diamorphine. The most frequently observed adverse effect is respiratory depression. Some adverse effects are relatively minor, such as drowsiness or itching. Hospital doctors are more likely than general practitioners to report having observed adverse effects.

Concerns about diamorphine tend to be focused on recognized risks, such as respiratory depression or respiratory failure, rather than addiction. Only 7% of doctors in one survey reported worries about the risks of addiction. General practitioners are less likely than hospital doctors to express worries about the use of diamorphine.

Despite its long history of use in British medicine and its establishment as a useful medication, there is a relative scarcity of well-controlled trials of the effectiveness of diamorphine. The future of diamorphine in medicine is likely to depend on the accumulation of improved evidence about its applications and effectiveness.

Diamorphine Use in British Medical Practice: A Detailed Look

Source: Gossop, M., Keaney, F., Sharma, P., & Jackson, M. (2005). The Unique Role of Diamorphine in British Medical Practice: A Survey of General Practitioners and Hospital Doctors. European Addiction Research, 11(2), 76–82. https://doi.org/10.1159/000083036

I. Introduction: This section establishes the historical context of diamorphine use in British medicine, highlighting the unique and often misunderstood nature of its routine use for general medical conditions, separate from its application in opiate addiction treatment. It also differentiates diamorphine’s accepted role in the UK from the controversial or prohibitive stance held in other countries.

II. History of Diamorphine Use: This section delves into the origins and evolution of diamorphine use, from its initial synthesis in 1874 to its early applications for a diverse range of medical conditions. It traces the trajectory of diamorphine’s application in the UK, contrasting its widespread use in general medicine with its limited role in the treatment of opiate addiction, which is strictly controlled and subject to specific licensing.

III. Current Study Methodology: This section outlines the methodology employed in the present study, which focuses on understanding the contemporary practices, beliefs, and concerns of British medical practitioners regarding diamorphine use for general medical conditions. It describes the study population, recruitment process, data collection methods, and ethical considerations.

IV. Results: Prescribing Practices: This section presents the study’s key findings, focusing on the prescribing practices of general practitioners (GPs) and hospital doctors. It reveals the types of medical conditions commonly treated with diamorphine, the frequency of its use, and the typical dosage, route of administration, and duration of treatment. The section also highlights notable differences in prescribing practices between GPs and hospital doctors.

V. Results: Concerns and Adverse Effects: This section explores the concerns and reservations expressed by medical practitioners regarding diamorphine prescribing, with a particular focus on worries about respiratory depression, addiction, and legal issues. It also details the observed adverse effects associated with diamorphine administration, noting the differences in observed adverse effects between GPs and hospital doctors, emphasizing the influence of clinical settings and observation opportunities.

VI. Discussion: Interpretation of Findings: This section analyzes and interprets the study’s findings, discussing the implications of the observed diamorphine prescribing practices and the reported concerns and adverse effects. It emphasizes the variations in diamorphine use based on specific medical conditions and the need for evidence-based decision-making in navigating the complexities surrounding diamorphine’s role in medicine.

VII. Conclusion: Future of Diamorphine in Medicine: This section summarizes the study’s conclusions, highlighting the enduring legacy of diamorphine use in British medicine and its integration into routine clinical practice. It advocates for further research and evidence-based approaches to inform future policy decisions and clinical practices related to diamorphine use. It also acknowledges the potential for increased scrutiny and regulatory changes surrounding diamorphine prescribing and stresses the importance of robust evidence to guide its continued application in medicine.

Diamorphine, also known as heroin, is a semi-synthetic derivative of morphine with a long history of use in British medicine. While it is unavailable for medical use in most countries, it has been used for over 100 years in the UK to treat a variety of conditions. Diamorphine is most often used for pain relief, specifically for conditions such as palliative care, myocardial infarction, and postoperative pain.

Benefits:

●

Diamorphine is more soluble than morphine and can be administered in a smaller volume.

●

It causes less nausea and hypotension than morphine.

●

When administered parenterally, diamorphine is preferred to morphine in palliative care.

●

It is effective for pain relief during labor and after cesarean section.

●

Diamorphine has been used effectively to treat acute pain in children and reduce stress in ventilated newborns.

Risks:

●

Respiratory depression is the most frequent adverse effect observed after diamorphine administration.

●

Other adverse effects include nausea, vomiting, constipation, itching, respiratory arrest, hypotension, addiction, sedation, drowsiness, and confusion.

●

Concerns about addiction and dependence have contributed to an exaggerated fear of diamorphine use among some medical professionals. This fear may lead to reluctance to prescribe effective doses of the drug.

●

Although some doctors reported observing addiction in patients given diamorphine, the majority did not report any special concerns about its medical use.

●

It’s important to note that the sources do not provide specific rates or probabilities for the risks associated with diamorphine use.

The use of diamorphine in medicine is often surrounded by strong opinions and misinformation. The authors of the source argue that more research is needed to understand the applications and effectiveness of diamorphine fully and to ensure that its use is based on evidence-based decision-making.